Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Disc MedicineIRON +1.17%35 3-Year EBITDA Growth Rate is 49.50% as of Jun. 2026, which is at its 10-year median of 49.50. GuruFocus rates IRON with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,129 Biotechnology companies, Disc Medicine ranks better than 85.12% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 49.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 25.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Disc Medicine was 51.90% per year. The lowest was 22.80% per year. And the median was 49.50% per year.
Disc Medicine (NAS:IRON) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Disc Medicine 3-Year EBITDA Growth Rate Related Terms
IRON vs CLDX, MBX, QURE: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Disc Medicine's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disc Medicine 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Disc Medicine's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Disc Medicine's 3-Year EBITDA Growth Rate falls into.
Disc Medicine 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 49.50% mean?
Disc Medicine (IRON) has a 3-Year EBITDA Growth Rate of 49.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Disc Medicine and its competitors. This is near median its historical median of 49.50. Over the past decade, Disc Medicine's 3-Year EBITDA Growth Rate has ranged from 22.80 to 51.90. According to the industry distribution chart, Disc Medicine ranks #168 out of 1129 companies in the Biotechnology industry, placing it in the top 14.9%.
Is Disc Medicine's 3-Year EBITDA Growth Rate too high?
Disc Medicine's current 3-Year EBITDA Growth Rate of 49.50% is near median its 10-year median of 49.50. Over the past 10 years, this metric has ranged from a low of 22.80 to a high of 51.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Disc Medicine's value of 49.50% is 236.7% above this industry median. Based on the distribution chart, Disc Medicine ranks #168 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Disc Medicine has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's 3-Year EBITDA Growth Rate compare to CLDX and MBX?
According to the Biotechnology industry distribution chart, Disc Medicine ranks #168 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Disc Medicine in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Disc Medicine's value of 49.50% is 236.7% above this benchmark. Historically, Disc Medicine's own 3-Year EBITDA Growth Rate has ranged from 22.80 to 51.90 over the past decade. While the company's 10-year median is 49.50 vs. the industry median of 14.70, Disc Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Disc Medicine's current 3-Year EBITDA Growth Rate of 49.50% is 236.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Disc Medicine and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disc Medicine's current 3-Year EBITDA Growth Rate is 49.50%, which is near median its own 10-year median of 49.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current 3-Year EBITDA Growth Rate of 49.50%. The current 3-Year EBITDA Growth Rate is 49.50%, which is near median its 10-year median of 49.50 and 236.7% above the Biotechnology industry median of 14.70. Disc Medicine's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Disc Medicine (IRON), the current 3-Year EBITDA Growth Rate is 49.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
35GF Score
Get the complete analysis for IRON
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRON has been successfully added to your 
